3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Neoplasms
19
Breast Neoplasms
17
Lung Neoplasms
10
Carcinoma, Non-Small-Cell Lung
7
Prostatic Neoplasms
5
Melanoma
5
Colorectal Neoplasms
5
Brain Neoplasms
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Carcinoma, Hepatocellular
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Myeloproliferative Disorders
3
Leukemia, Myeloid, Acute
3
Kidney Neoplasms
3
Head and Neck Neoplasms
3
Uveal Melanoma
2
Recurrence
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Lung Diseases
2
Glioma
2
Glioblastoma
2
Genetic Predisposition to Disease
2
Fibrosis
2
Interventions
fludarabine
2
Cyclophosphamide
2
cabozantinib
1
Specimen Handling
1
Platinum Compounds
1
Nivolumab
1
Ipilimumab
1
Injections
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Sclerosis
×
Blood Specimen Collection
×
90 days
×
Clear all
NCT00704626
2026-05-18
SAA
University of California, Davis
Enrolling by invitation
120 enrolled